Analyst Price Targets — NR
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 6, 2024 7:44 am | Alex Rygiel | B.Riley Financial | $11.00 | $7.10 | StreetInsider | Newpark Resources (NR) PT Raised to $11 at B.Riley |
| April 9, 2024 2:54 am | Alex Rygiel | B.Riley Financial | $10.00 | $7.73 | StreetInsider | B.Riley Starts Newpark Resources (NR) at Buy, 'platform for attractive growth' |
Latest News for NR
Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia
[url="]Niagen Bioscience, Inc.[/url] (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy ag
TiumBio to Present Phase 2a Interim Data Highlighting Differentiated Clinical Profile for Tosposertib(TU2218) plus Pembrolizumab in First-Line R/M HNSCC at ASCO 2026
TiumBio to Present Phase 2a Interim Data Highlighting Differentiated Clinical Profile for Tosposertib(TU2218) plus Pembrolizumab in First-Line
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for NR.
U.S. House Trading
No House trades found for NR.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.